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Hyperphosphatemia and cardiovascular disease
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SUMMARY
Hyperphosphatemia has been known as a risk factor for cardiovascular disease particularly in
chronic kidney disease patients. Hyperphosphatemia can be involved in the calcification of vascular
¨smooth muscle cells, resulting in Monkeberg medial calcific sclerosis which is a type of arterioscle-
rosis. However, it has not been clarified whether hyperphosphatemia can deteriorate endothelial
function and can be a risk factor of atherosclerosis. Our recent study demonstrated that hyper-
phosphatemia increased oxidative stress and decreased nitric oxide production in endothelial cells.
In addition, hyperphosphatemia attenuated endothelium-dependent vasodilation reaction. These
observations suggest that hyperphosphatemia may cause endothelial dysfunction, and be an impor-
tant factor for progression of atherosclerosis as well as vascular calcification. Positive association
between hyperphosphatemia and cardiovascular disease may be explained by the dual harmful
effects of phosphorus on the vessels.
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